Arcellx
ACLX
NASDAQ
IPO2022
about ACLX
Arcellx is a biopharmaceutical company focused on developing innovative antibody-drug conjugates (ADCs) to target and treat various cancers by delivering potent anti-cancer agents directly to cancer cells while minimizing harm to healthy tissue.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $114.14 | $114.26 | $113.70 | $3.7B | 32.90M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$0.99 | n/a | 1300.62 | -1248.25% | -1127.12% | 0% |